METAGLIP
LOE ApproachingNDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METAGLIP is an oral tablet small-molecule antidiabetic product approved in 2002 by Bristol Myers Squibb. The specific mechanism of action and indications are not disclosed in available data, but the product name suggests a combination therapy targeting metabolic pathways in diabetes management. METAGLIP is a mature marketed product now approaching loss of exclusivity.
LOE Approaching
Product is in late-stage maturity with moderate competitive pressure (30/100), indicating a contracting team and focus on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
METAGLIP has zero linked job openings and represents a contracting product portfolio opportunity. Career development on this asset is limited; opportunities are primarily in defensive sales, managed care advocacy, and transition planning as the product approaches generic competition.
Field Sales RepresentativeBrand Manager
Worked on METAGLIP at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.